ABBV — Phase 3 Venetoclax + Azacitidine AML Trial Completion
Jan 23, 2026, 5:00:00 AM UTC
Summary
AbbVie is conducting a global Phase 3, randomized, double-blind, placebo-controlled trial (NCT02993523) evaluating venetoclax in combination with azacitidine versus azacitidine alone in treatment-naïve adults with acute myeloid leukemia (AML) ineligible for standard induction therapy. The study, enrolling 443 participants across approximately 180 sites, is expected to complete on January 23, 2026. Venetoclax is a BCL-2 inhibitor targeting cancer cell survival, and azacitidine is a hypomethylating agent. The trial's outcome may impact future AML treatment protocols.
Company
ABBVIE INC (ABBV)NYSE — Healthcare: Manufacturing, Drug Manufacturers - General: Pharmaceutical Preparations
www.abbvie.comSimilar Events
Phase 3 trial completion: Venetoclax + Azacitidine in higher-risk MDS
AbbVie is expected to complete a Phase 3 clinical trial (NCT04401748) on September 10, 2025, evaluating the combination of venetoclax and azacitidine versus azacitidine plus placebo in adults with newly diagnosed higher-risk myelodysplastic syndrome (MDS). Venetoclax is an investigational BCL-2 inhibitor, while azacitidine is a hypomethylating agent approved for MDS. The study aims to assess efficacy and safety in approximately 531 participants across 220 global sites. Results may inform future regulatory submissions for venetoclax in MDS.
trial completionClinical Trial Completion for Venetoclax and Azacitidine in Higher-Risk MDS
AbbVie is conducting a Phase 1b clinical trial evaluating venetoclax in combination with azacitidine for treatment-naïve patients with higher-risk myelodysplastic syndromes (MDS). The study, which began in January 2017 and is no longer recruiting, is expected to complete on January 8, 2027. Venetoclax is a BCL-2 inhibitor approved for certain hematologic malignancies, while azacitidine is a hypomethylating agent used in MDS. The trial's outcome may inform future regulatory or clinical decisions for this patient population.
trial completionVenetoclax Phase I AML Trial Completion
A Phase I clinical trial evaluating venetoclax in combination with daunorubicin and cytarabine for treatment-naïve acute myeloid leukemia (AML) patients is expected to complete on June 1, 2026. The study, sponsored by Dana-Farber Cancer Institute, aims to determine the safety and optimal dosing of venetoclax in this setting. Venetoclax, marketed by AbbVie, is already approved for other hematologic malignancies but remains investigational for AML in this combination. The trial's outcome may inform future development and regulatory strategies for venetoclax in AML.
trial completionClinical Trial Completion for Venetoclax Combination in Multiple Myeloma
AbbVie is conducting a Phase 2 clinical trial evaluating venetoclax in combination with carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma. The study, which began in January 2017 and is currently active but not recruiting, is expected to complete on June 22, 2027. Venetoclax is a BCL-2 inhibitor approved for certain hematologic malignancies, and this trial explores its use in a new combination regimen for multiple myeloma, a cancer of plasma cells. The trial enrolls 120 participants and aims to assess safety and efficacy outcomes.
trial completion